THE LEADING RNAi THERAPEUTICS COMPANY
Alnylam has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases in a different way - by silencing the genes that cause or contribute to them. We are working diligently to develop RNAi-based medicines to benefit as many patients as possible.
About Alnylam
We are a biopharmaceutical company driven by science and committed to delivering transformational medicines for patients.
Our Pipeline
Our robust pipeline of investigational RNAi therapeutics is focused on both rare and prevalent diseases in several therapeutic areas.
Corporate Responsibility
We believe that Alnylam can have a positive impact on the world beyond the medicines we make and embrace the opportunity to be a force for good.
SILENCING GENES TO TREAT DISEASE
RNA interference (RNAi) is a naturally occurring process already at work inside your body which regulates how genes make new proteins. Proteins play a critical role in almost everything your body does, but sometimes, they can cause or contribute to disease. Our medicines leverage the RNAi process to selectively target and prevent specific proteins from being made, “silencing” gene expression to treat disease at its source.
DRIVEN BY SCIENCE, INSPIRED BY PEOPLE
Whether we're working to develop the first treatment for a disease, or a better one, patients are at the center of all we do. They are the reason we come to work every day, and their stories inspire us to continue innovating by pushing the science of RNAi therapeutics forward.
JOIN US
Incredible things happen when science and culture come together, and we believe that our people are our greatest strength. Together, we have built an inclusive, exceptional workplace where everyone can do their best work. To those who say impossible, impractical, unrealistic, we say, Challenge Accepted.